Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in OCD
NCT05546658Phase 1Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocybin in obsessive compulsive disorder (OCD) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Yale Brown Obsessive Compulsive Scale, State-Trait Anxiety Inventory and 2 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT05546658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546658.